- cafead Oct 28, 2019 at 11:22: AM
via Back in 2015, Vertex made a splash in the nascent CRISPR gene editing world by wagering $105 million to partner with one of its pioneers — then-private startup CRISPR Therapeutics — to generate up to six new treatments for genetic diseases.
Fast forward four years, the duo has accomplished the historic feat of dosing their ex vivo therapy, CTX001, in patients with beta thalassemia, and Vertex has clearly signaled its intent on going bigger into gene editing tech.
article source
Fast forward four years, the duo has accomplished the historic feat of dosing their ex vivo therapy, CTX001, in patients with beta thalassemia, and Vertex has clearly signaled its intent on going bigger into gene editing tech.
article source